Abstract:

A 76-year-old woman with hereditary hemorrhagic telangiectasia (HHT) showed elevated serum hepatobiliary enzyme levels, and abdominal imaging studies revealed a hepatic tumor. Her serum alpha-fetoprotein level was 759.5 ng/mL. A pathological examination after hepatectomy confirmed a diagnosis of hepatocellular carcinoma (HCC). An examination of the surrounding liver revealed dilated vessels and thickened endothelial cells without inflammations. HHT patients without other risk factors (like this patient) reportedly have a lower incidence of common cancers, including HCC, in comparison to the unaffected population. One intriguing hypothesis that might explain the hepatocarcinogenesis in this situation is the ischemic liver cirrhosis theory, which suggests that chronic ischemia may cause parenchymal strain and promote inappropriate hepatocyte proliferation.

Key words: hepatocellular carcinoma, hereditary hemorrhagic telangiectasia, vascular malformation, focal nodular hyperplasia, ischemic liver cirrhosis theory

Introduction

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disease with a prevalence of approximately 1 case per 5,000 population (1). HHT is related to mutations in two genes, endoglin or ALK1, which encode the type III and type I transforming growth factor-β receptors, respectively. Both are exclusively expressed on vascular endothelial cells (2). A wide range of vascular malformations (VMs) develop in patients with HHT. Hepatic VMs include telangiectasias, dilated tortuous vessels, aneurysms, various vascular shunts, and transient hepatic attenuation differences (3). They are observed in 41-84% of HHT patients, and are more commonly associated with ALK1 mutation (HHT-2 phenotype) (4). These VMs can cause hepatic parenchymal hypo-perfusion or hyper-perfusion depending on their location, which may induce regenerative responses including nodular transformation, focal nodular hyperplasia (FNH), and nodular regenerative hyperplasia (3, 5, 6). Importantly, these hepatic nodules are benign conditions in nature, and HHT patients with no other risk factors have been reported to rarely develop hepatocellular carcinoma (HCC) (7), or to develop HCC less frequently than the general population (8). We herein present a very rare case of HCC in a HHT patient without any other predisposing factors and discuss the possible associations between the hepatocarcinogenesis and hepatic VMs in HHT patients. This case highlights the importance of considering HCC as a potential diagnosis when HHT patients present with hepatic nodular lesions.

Case Report

A 76-year-old woman was referred to our department for the evaluation of elevated liver enzyme levels, which were detected when gastric bleeding from angiodysplasia was treated with endoscopic hemostasis clips (Fig. 1). Her significant medical history included HHT, which had been diagnosed based on the Curaçao criteria (4). The patient re-
ported no abdominal pain or weight loss, nor did she report drinking alcohol, smoking cigarettes, or taking any medications. Conjunctival anemia, small telangiectasias on her lips and tongue, and cardiac enlargement with systolic murmur were noted during a physical examination. The liver span was 5 cm below the right costal margin, with no tenderness to palpation. Laboratory test results revealed the following: hemoglobin, 10.5 g/dL; International Normalized Ratio, 1.05; total bilirubin, 1.0 mg/dL; albumin, 3.7 g/dL; and hemoglobin, 10.5 g/dL; International Normalized Ratio, 1.05. Cerulean hepatitis, and tongue, and cardiac enlargement with systolic murmur were noted during a physical examination. The liver span was 5 cm below the right costal margin, with no tenderness to palpation. Laboratory test results revealed the following: hemoglobin, 10.5 g/dL; International Normalized Ratio, 1.05; total bilirubin, 1.0 mg/dL; albumin, 3.7 g/dL; and hemoglobin, 10.5 g/dL; International Normalized Ratio, 1.05. Cerulean hepatitis, and tongue, and cardiac enlargement with systolic murmur were noted during a physical examination. The liver span was 5 cm below the right costal margin, with no tenderness to palpation.

The imaging findings combined with the elevated serum alpha-fetoprotein suggested a diagnosis of HCC. Hepatic angiography showed few large VMs near the boundary between the HCC and the hepatic right lobe (Fig. 4). Despite the risk of perioperative bleeding due to HHT, a decision was made to perform partial hepatectomy, based on the absence of both clinically significant portal hypertension and large VMs near the HCC. The postoperative course was uneventful.

The cut surface of the resected tumor showed an encapsulated, well-circumscribed lobulated solid lesion measuring 85×70×50 mm, with intratumoral hemorrhage (Fig. 5, left). The microscopic examination of the tumor confirmed the diagnosis of moderately differentiated HCC (Fig. 5, right upper). The surrounding hepatic parenchyma was noncirrhotic and showed abnormally dilated vessels, thickened endothelial cells, dilated sinusoids, and intervening fibrosis with no inflammatory changes or iron deposits (Fig. 5, right lower). Unfortunately, a recurrent hepatic tumor developed 8 months postoperatively, and grew to occupy the entire liver, metastases to the lung, and metastases to the lung.

![Figure 1](image)

**Figure 1.** Esophagogastroduodenoscopy revealed multiple gastric angiodysplasias (arrows). Bleeding from one of these lesions was treated with endoscopic hemostasis clips.

**Table. Laboratory Test Results on Initial Evaluations.**

| Variables                | Reference Ranges | This Patient | Variables                | Reference Ranges | This Patient |
|--------------------------|------------------|--------------|--------------------------|------------------|--------------|
| Hemoglobin, g/dL         | 10.7-15          | 10.5         | Triglycerides, mg/dL     | 50-150           | 120          |
| Hematocrit, %            | 34.4-44          | 32.9         | Iron, μg/dL              | 50-150           | 36           |
| Red-cell count, 10⁹/mm³  | 3,700-4,900      | 3,150        | Iron-binding capacity, μg/dL | 253-365         | 332          |
| White-cell count, /mm³   | 3,300-8,600      | 3,700        | Ferritin, ng/mL          | 13-277           | 13           |
| Platelet count, 10⁹/mm³  | 140-360          | 221          | Copper, μg/dL            | 68-128           | 86           |
| International normalized | 1.05             |              | Ceruloplasmin, mg/dL     | 21-37            | 25           |
| Activated partial-thromboplastin time, sec | 23-40       | 32           | Ammonia, μmol/L          | 12-66            | 54           |
| Fibrinogen, mg/dL        | 170-400          | 335          | C-reactive protein, mg/L  | 0-3.0            | 2.8          |
| Total protein, g/dL      | 6.7-8.3          | 6.8          | Immunoglobulin G, mg/dL  | 870-1,700        | 1,596        |
| Albumin, g/dL            | 4.1-5.1          | 3.7          | Antinuclear antibodies   | negative         |              |
| Total bilirubin, mg/dL   | 0.4-1.5          | 1.0          | Antimitochondrial antibody | negative       |              |
| Aspartate aminotransferase, U/L | 13-33    | 22.0         | Alpha-fetoprotein, mg/mL  | 0-10             | 759.5        |
| Alanine aminotransferase, U/L | 6-42       | 9            | Des-γ-carboxy prothrombin, mAU/mL | <40           | 2,068        |
| Lactate dehydrogenase, U/L | 119-229     | 206          | Carcinoembryonic antigen, mg/mL | 0-5          | 1.5          |
| Alkaline phosphatase, U/L | 115-359     | 490          | Carbohydrate antigen 19-9, U/mL | 0-37        | 10.2         |
| Gamma-glutamyl transpeptidase, U/L | 10-47     | 94           | Hepatitis B virus surface antigen | negative     |              |
| Urea nitrogen, mg/dL     | 8-20             | 20.4         | Hepatitis B virus DNA    | negative         |              |
| Creatinine, mg/dL        | 0.2-0.8          | 1.1          | anti-Hepatitis B virus surface antigen | negative    |              |
| Glucose, mg/dL           | 70-110           | 94           | anti-Hepatitis B virus core antigen | negative    |              |
| Hemoglobin A1c, %        | 4.3-5.8          | 4.1          | anti-Hepatitis C virus   | negative         |              |
| Total cholesterol, mg/dL | 130-220          | 164          | Hepatitis C virus RNA    | negative         |              |
Patients with HHT often develop multiple vascular abnormalities including pulmonary, cerebral, spinal, and hepatic VMs. The mortality rate of HHT patients of <60 years of age is higher in comparison to the age-adjusted unaffected population, due to cerebral VM bleeds and pregnancy-related death (9-11). However, HHT patients of ≥60 years of age have surprisingly good survival rates (12). In this older population, HHT-related mortality may be offset by a reduction in deaths from common life-threatening diseases, including cancers. Clinical observational studies indicated that HHT patients showed lower rates of specific types of cancer-including lung and liver cancer-in comparison to controls (8). Actually, there are few reports of the development of HCC in HHT patients who have no other risk factors (7). Another large retrospective cohort study suggested that HHT patients had improved survival outcomes in multiple cancers (13).

The consequences of the mutation of endoglin or ALK1 are complex and may depend on the location of its expression, such as in cancer cells, stroma, or vascular compartments (14-16). Laboratory and animal studies have shown that endoglin and ALK1 apparently have opposing effects on the carcinogenic signaling pathway. For example, a study using human prostate cancer cell line models demonstrated that the overexpression of endoglin inhibited tumor cell invasion and metastasis (anti-metastatic) (17). On the other hand, a study using mouse model of prostate cancer indicated that endoglin was required for tumor vascularization and metastatic spread by cancer-associated myofibroblasts (pro-metastatic) (18). In any case, clinical observational studies indicate that mutations of endoglin or ALK1 do not usually increase the specific cancer incidence in real world cohorts (5, 6, 8).

FNHs and nodular regenerative hyperplasia are sometimes encountered in patients with HHT (3, 5, 6). Some authors have hypothesized that FNH and nodular regenerative hyperplasia may transform into, or be associated with HCC (19, 20). Others have reported that HCC had different origins from FNH based on a clonal analysis (21, 22). In the present case, neither FNHs nor nodular regenerative hyperplasias were observed; thus, it was unlikely that the patient’s
HCC emerged from such hyperplastic lesions.

Then, what is a plausible explanation for the occurrence of HCC in this patient? An alternate, intriguing hypothesis is “the ischemic liver cirrhosis theory” (23). It is widely recognized that hepatocarcinogenesis is driven by both the altered intracellular signaling pathways and the hepatic microenvironment. HCCs often develop in a background of cirrhosis which is accompanied by decreased oxygen delivery to the liver cells (24). In this patient, hepatic microvascular and perfusion abnormalities may have caused endothelial damage, sinusoidal thrombosis, and chronic regional hypoxia, leading to hepatic parenchymal strain and extinction with the promotion of fibrosis. This hypoxic microenvironment could also induce a key transcription factor, hypoxia-inducible factor-1α, which influences signaling pathways involved in angiogenesis, cell growth and survival, and apoptosis, resulting in the transactivation of a plethora of genes to evoke genetic instability and inappropriate hepatocyte proliferation (25, 26). The tipping of the balance of these pathways might have been critical for the hypoxia-induced carcinogenic processes.

There are few reports of hepatectomy in patients with HHT, with the exception of hepatectomy for liver transplantation (27). Widespread hepatic VMs may lead to portal hypertension, hepatic parenchymal and/or biliary ischemia, and high-output cardiac failure. All of these are associated with the risk of peri-operative bleeding and hepatic functional compromise. We decided to perform hepatectomy based on the absence of both distinct VMs near the surgical margins and clinically significant portal hypertension. Our experience has shown that major hepatectomy can be safely performed in carefully selected HHT patients.

The administration of bevacizumab, a vascular endothelial growth factor (VEGF) antibody, reportedly led to a regression of hepatic VMs, portal hypertension, and high-output cardiac failure in patients with HHT (28, 29). If the patient’s condition had been eligible for anti-cancer treatment at the time of postoperative recurrence, the antagonism of VEGF might have been a beneficial treatment approach for both HCC and HHT.

In conclusion, we reported a case of HCC and HHT. Benign hepatic nodules, such as FNH and nodular regenerative hyperplasia sometimes develop in patients with HHT; however, HCC seldom occurs in this situation. One intriguing hypothesis that might explain the hepatocarcinogenesis in this situation is the ischemic liver cirrhosis theory. Our ex-
perience showed that major hepatectomy can be safely performed in carefully selected patients with HHT. Anti-VEGF therapy may be applicable for both HCC and HHT in this rare situation.

The authors state that they have no Conflict of Interest (COI).

References

1. Dakeishi M, Shiroya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 19: 140-148, 2002.
2. Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest 47: 81-90, 2000.
3. Scardapani A, Ficco M, Sabbà C, et al. Hepatic nodular regenerative lesions in patients with hereditary haemorrhagic telangiectasia: computed tomography and magnetic resonance findings. Radiol Med 118: 1-13, 2013.
4. Faughnan ME, Palla VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48: 73-87, 2011.
5. Singh S, Swanson KL, Hatrick MA, et al. Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index. J Hepatol 61: 124-134, 2014.
6. Brenard R, Chapaux X, Deltenne P, et al. Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. Eur J Gastroenterol Hepatol 22: 1253-1259, 2010.
7. Jameson CF. Primary hepaticcellular carcinoma in hereditary haemorrhagic telangiectasia: a case report and literature review. Histopathology 15: 550-552, 1989.
8. Rosier ME, Devlin HL, Silva BM, et al. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 8: 195, 2013.
9. Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 47: 711-720, 2005.
10. Sabbà C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 99: 327-334, 2006.
11. Shovlin CL, Sudoh V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 115: 1108-1115, 2008.
12. de Gussem EM, Edwards CP, Hosman AE, et al. Life expectancy of parents with Hereditary Haemorrhagic Telangiectasia. Orphanet J Rare Dis 11: 46, 2016.
13. Duarte CW, Murray K, Lucas FL, et al. Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev 23: 117-125, 2014.
14. Massagué J. TGFbeta in Cancer. Cell 134: 215-230, 2008.
15. Mitchell D, Pobere EG, Mulivor AW, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9: 379-388, 2010.
16. Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18: 4820-4829, 2012.
17. Lakshman M, Huang X, Ananthanarayanan V, et al. Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28: 39-53, 2011.
18. Romero D, O’Neill C, Terzie A, et al. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 71: 3482-3493, 2011.
19. Nizeko UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol 91: 879-884, 1996.
20. Langrehr JM, Pfützmann R, Hermann M, et al. Hepatocellular carcinoma in association with hepatic focal nodular hyperplasia. Acta Radiol 47: 340-344, 2006.
21. Chen TC, Chou TB, Ng KF, et al. Hepatocellular carcinoma associated with focal nodular hyperplasia. Report of a case with clonal analysis. Virchows Arch 438: 408-411, 2001.
22. Kellner U, Jacobsen A, Kellner A, et al. Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations. Am J Clin Pathol 119: 265-271, 2003.
23. Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Med Hypotheses 94: 4-6, 2016.
24. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2: 16018, 2016.
25. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
26. Bogaerts E, Heindryckx F, Vandewynckel YP, et al. The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours. Int J Oncoi 44: 1015-1022, 2014.
27. Gaynor C, Bucau M, Ronot M, et al. Liver resection in patients with hepatic hereditary hemorrhagic telangiectasia. Dig Surg 30: 410-414, 2013.
28. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14: 210-213, 2008.
29. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307: 948-955, 2012.